Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of AR117446A1publicationCriticalpatent/AR117446A1/en
La presente solicitud describe anticuerpos anti-PMEL17, fragmentos de unión a antígeno de los mismos, y conjugados de anticuerpo fármaco de dichos anticuerpos o fragmentos de unión a antígeno conjugados a un inhibidor de GNAQ / GNA11. La presente además se refiere a métodos para tratar o prevenir el cáncer usando los anticuerpos, fragmentos de unión a antígeno, y conjugados de anticuerpo fármaco. Además se describen métodos de preparación de anticuerpos, fragmentos de unión a antígeno, y conjugados de anticuerpo fármaco, y métodos de uso de los anticuerpos y fragmentos de unión a antígeno como reactivos de diagnóstico.The present application describes anti-PMEL17 antibodies, antigen-binding fragments thereof, and drug antibody conjugates of such antibodies or antigen-binding fragments conjugated to a GNAQ / GNA11 inhibitor. The present further relates to methods of treating or preventing cancer using the antibodies, antigen-binding fragments, and antibody-drug conjugates. In addition, methods of preparing antibodies, antigen-binding fragments, and antibody-drug conjugates, and methods of using the antibodies and antigen-binding fragments as diagnostic reagents are described.
ARP190103765A2018-12-212019-12-19
ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF
AR117446A1
(en)
ANTIBODY OR ANTIGEN-BINDING FRAGMENT OF THE SAME THAT SPECIFICALLY BINDS TO HUMAN LAG3, COMPOSITION, AND, USE OF THE ANTIBODY OR AN ANTIGEN-BINDING FRAGMENT OF THESE AND THE COMPOSITION
anti-cd123 antibody drug conjugated compound, antibody drug conjugated composition, method of treating a patient having a cd123 expressing cancer, pharmaceutical composition, and intact antibody or antigen binding fragment
Isolated antibody or antigen-binding fragment thereof, pharmaceutical composition, and methods for treating a cancer or tumor expressing egfrviii and for treating a cancer, reducing tumor growth and / or causing tumor regression in a patient ?